LFG
NRIX icon

Larson Financial Group’s Nurix Therapeutics NRIX Stock Holding History

Larson Financial Group’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.7K Sell
441
-4
-0.9% -$68 ﹤0.01% 2363
2026
Q1 		$6.9K Sell
445
-1,096
-71% -$18.2K ﹤0.01% 2440
2025
Q4 		$29.2K Buy
1,541
+1,190
+339% +$17.1K ﹤0.01% 1498
2025
Q3 		$3.24K Buy
+351
New +$3.65K ﹤0.01% 2516
2024
Q4 		– Sell
-24
Closed -$539 – 2860
2024
Q3 		$539 Buy
+24
New +$544 ﹤0.01% 2106

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Larson Financial Group's NRIX Position: Q2 2026 in Review

Larson Financial Group reduced its Nurix Therapeutics (NRIX) stake by 0.9% in Q2 2026, selling an estimated $68 and leaving 441 shares worth $10.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2363.

Larson Financial Group first reported a position in NRIX in Q3 2024 and has held it in 5 quarters since. The position peaked at $29.2K in Q4 2025. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Larson Financial Group held 441 shares of Nurix Therapeutics worth $10.7K as of Q2 2026.
  • Larson Financial Group sold 4 Nurix Therapeutics shares in Q2 2026, an estimated $68.
  • Nurix Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #2363 holding.
  • Larson Financial Group first reported a position in Nurix Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • Larson Financial Group's Nurix Therapeutics position peaked at $29.2K in Q4 2025.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.